Invivyd provides virology data showing PEMGARDA neutralization potency stable against current SARS-CoV-2 variants

Invivyd, Inc.

In vitro neutralization potency of PEMGARDA against KP.3.1.1 and LB.1 variants remains in-line with prior predominant variants dating to 2022.
Structural analysis shows 19-key-amino-acid pemivibart binding site has de minimis mutational change and 99%+ stability since Omicron BA.1.
Emerging variants XEC and LP.1 have mutations distal to binding site, not expected to meaningfully alter pemivibart activity; routine testing follows.
Data from independent LabCorp Monogram Biosciences lab; company expects sustained neutralization based on structural biology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.